Stifel Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM)

July 24, 2026 9:48 AM

Stifel analyst James Condulis reiterated a Buy rating and $136.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented: "Ipsen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found